David Natan - 26 Jul 2023 Form 4/A - Amendment Insider Report for TITAN PHARMACEUTICALS INC (TTNP)

Reporting relationship: Director
Issuer ticker: TTNP
Reported as of: 26 Jul 2023
Net transaction value: $0
SEC form: 4/A - Amendment
Accepted by SEC: 31 Jul 2023, 19:45:55 UTC
Original report date: 28 Jul 2023
Prior SEC filing: 19 Dec 2022
Next SEC filing: 26 Oct 2023
Source filing: View source filing
Reporting owner signature: /s/ David Natan

Key filing fact

David Natan filed Form 4/A - Amendment for TITAN PHARMACEUTICALS INC (TTNP) on 31 Jul 2023.

Key facts

This page summarizes David Natan's Form 4/A - Amendment filing for TITAN PHARMACEUTICALS INC (TTNP).
3 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 31 Jul 2023, 19:45.

Change

Previous filing in this sequence was filed on 19 Dec 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TTNP transaction

Common Stock

Award

Transaction value: $0
Shares: +50,000
Change %
Price: $0.000000
Shares after: 50,000
Date: 26 Jul 2023
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TTNP transaction Derivative

Option to Purchase Common Stock

Award

Transaction value: $0
Shares: +25,000
Change %
Price: $0.000000
Shares after: 25,000
Date: 29 Jun 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 25,000
Exercise price: $1.52
Footnotes: F2, F3

TTNP transaction Derivative

Option to Purchase Common Stock

Award

Transaction value: $0
Shares: +100,000
Change %
Price: $0.000000
Shares after: 100,000
Date: 29 Jun 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 100,000
Exercise price: $1.31
Footnotes: F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The shares reported in this transaction represent Unrestricted Stock Awards pursuant to the Issuer's Fourth Amended and Restated 2015 Omnibus Equity Incentive Plan that vested immediately on the date of grant.

Footnote F2

The options were approved by the Issuer's Board of Directors on August 15, 2022. The options were conditioned on the approval by the Issuer's stockholders of an increase in the number of shares available for issuance under the 2015 Omnibus Equity Incentive Plan, which approval occurred on June 29, 2023. The exercise price of the options is equal to the closing price of the Issuer's common stock on August 15, 2022.

Footnote F3

This Form 4 is being amended to correct the expiration date of the options, which were incorrectly reported in the original report due to an inadvertent clerical error.

Footnote F4

The options were approved by the Issuer's Board of Directors on September 15, 2022. The options were conditioned on the approval by the Issuer's stockholders of an increase in the number of shares available for issuance under the 2015 Omnibus Equity Incentive Plan, which approval occurred on June 29, 2023. The exercise price of the options is equal to the closing price of the Issuer's common stock on September 15, 2022.